Results 11 to 20 of about 32,499 (205)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial [PDF]

Intensive Care Medicine, 2021
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).
Patrick Lawler, Charlotte Bradbury
exaly   +6 more sources

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials

Journal of Infection and Public Health, 2021
Background: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been ...
Tejas K. Patel, Parvati B. Patel, Manish Barvaliya, Manoj Kumar Saurabh, Hira Lal Bhalla, Prem Parkash Khosla   +5 more
doaj   +3 more sources

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Clinical Microbiology and Infection, 2021
Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronavirus 2019 disease (COVID-19 ...
François Goehringer, Alpha Diallo, Jean Reignier   +2 more
exaly   +2 more sources

Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

British Journal of Clinical Pharmacology, 2012
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Doubling the dose of lopinavir/ritonavir overcomes the effect of rifampicin on lopinavir concentrations. However, lopinavir concentrations are highly variable and side effects occur commonly.
Paolo Denti, Helen McIlleron, Ulrika S H Simonsson   +2 more
exaly   +2 more sources

Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo

Investigational New Drugs, 2019
We generated a nitric oxide (NO)-releasing derivative of the anti-HIV protease inhibitor lopinavir by linking the NO moiety to the parental drug. We investigated the effects of lopinavir and its derivative lopinavir-NO on melanoma cell lines in vitro and
Yousef Al-Abed, Mingzhu He, Sanja Mijatović   +2 more
exaly   +2 more sources

Inadequate Lopinavir Concentrations With Modified 8-hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV [PDF]

, 2023
Background: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated ...
Mulenga, Veronica, McIlleron, Helen, Chungu, Chalilwe, Choo, Louise, Tembo, Chimuka H, LeBeau, Kristen, Weisner, Lubbe, Crook, Angela, Gibb, Diana, Chabala, Chishala, Turkova, Anna, Zimba, Kevin, Zyambo, Khozya, Lungu, Joyce, SHINE trial team, Kapasa, Monica   +15 more
core   +5 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration [PDF]

, 2011
The relationship between lopinavir plasma concentration and the magnitude of lipid elevation after initiation of lopinavir/ritonavir-containing antiretroviral therapy is unclear.
Burger, David M., Sven A Danner, Michiel A van Agtmael, Veldkamp, Agnes I., van Vonderen, Marit G. A., Reiss, Peter, Agnes I Veldkamp, Danner, Sven A., Bierman, Wouter F. W., David M Burger, Peter Reiss, Wouter FW Bierman, van Agtmael, Michiel A., Marit GA van Vonderen   +13 more
core   +2 more sources

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Терапевтический архив, 2021
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of ...
Natalia Yu. Pshenichnaya, Elena N. Kareva, Irina A. Leneva, Vilya A. Bulgakova, Irina E. Kravchenko, Irina V. Nikolaeva, Antonina I. Grekova, Antonina P. Ivanova, Larisa V. Puzyreva, Guzel M. Khasanova, Svetlana N. Orlova, Elena P. Tikhonova, Vladimir A. Petrov, Oleg V. Malinin, Natalia V. Kolaeva, Elena V. Volchkova, Nina N. Kanshina, Vladimir P. Chulanov   +17 more
doaj   +1 more source

Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans—In Silico, In Vitro and In Vivo Approaches

Journal of Fungi, 2021
The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen Candida albicans ...
André L. S. Santos, Lys A. Braga-Silva, Diego S. Gonçalves, Lívia S. Ramos, Simone S. C. Oliveira, Lucieri O. P. Souza, Vanessa S. Oliveira, Roberto D. Lins, Marcia R. Pinto, Julian E. Muñoz, Carlos P. Taborda, Marta H. Branquinha   +11 more
doaj   +1 more source